ARTL:NSD-Artelo Biosciences Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.79

Change

+0.07 (+1.88)%

Market Cap

USD 0.01B

Volume

0.35M

Avg Analyst Target

USD 55.00 (+1,351.19%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ARTL Stock Forecast & Price:
Based on the Artelo Biosciences Inc stock forecasts from 1 analysts, the average analyst target price for Artelo Biosciences Inc is USD 55.00 over the next 12 months. Artelo Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Artelo Biosciences Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Artelo Biosciences Inc’s stock price was USD 3.79. Artelo Biosciences Inc’s stock price has changed by +905.31% over the past week, +957.18% over the past month and -71.13% over the last year.

About Artelo Biosciences Inc (ARTL:NSD)

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+2.36 (+0.81%)

USD74.93B 24.21 16.33
REGN Regeneron Pharmaceuticals Inc

+4.81 (+0.77%)

USD69.21B 12.88 9.34
MRNA Moderna Inc

-0.63 (-0.37%)

USD68.17B 5.42 4.08
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+1.76 (+1.11%)

USD38.32B 3.09 2.08
SGEN Seagen Inc

-3.90 (-2.24%)

USD32.10B 55.02 -46.75
RPRX Royalty Pharma Plc

+0.50 (+1.14%)

USD29.54B 42.84 20.93
ALNY Alnylam Pharmaceuticals Inc

+4.46 (+1.94%)

USD27.16B N/A -34.32
GMAB Genmab AS

-0.69 (-1.83%)

USD23.25B 72.63 6.37
ARGX argenx NV ADR

+2.77 (+0.74%)

USD20.75B N/A -20.02

ETFs Containing ARTL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -51.32% 31% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.32% 31% F 21% F
Trailing 12 Months  
Capital Gain -70.89% 28% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.89% 28% F 17% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.21% 53% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.21% 53% F 48% F
Risk Return Profile  
Volatility (Standard Deviation) 68.85% 37% F 19% F
Risk Adjusted Return 1.76% 52% F 42% F
Market Capitalization 0.01B 4% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.44 94% A 95% A
Price / Cash Flow Ratio -1.72 37% F 59% F
EV/EBITDA 1.28 11% F 48% F
Management Effectiveness  
Return on Equity -45.80% 62% D- 26% F
Return on Invested Capital -93.50% 23% F 11% F
Return on Assets -27.75% 46% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.80 62% D- 56% F
Short Percent 1.75% 69% D+ 62% D-
Beta 1.25 51% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector